Novel Metabolic Drugs and Blood Pressure: Implications for the Treatment of Obese Hypertensive Patients?
Authors:
- 10 August 2013
- journal article
- review article
- Published by Springer Nature in Current Hypertension Reports
- Vol. 15 (5) , 470-474
Abstract
Hypertension and obesity often coexist, exposing patients to cardiovascular and metabolic risks, particularly type 2 diabetes mellitus. Moreover, obesity may render hypertensive patients treatment resistant. We review how drugs recently approved for obesity or type 2 diabetes mellitus treatment affect blood pressure. The weight-reducing drug lorcaserin induces modest reductions in body weight while slightly improving blood pressure. The fixed low-dose topiramate/phentermine combinations elicit larger reductions in body weight and blood pressure. Concomitant improvements in glucose metabolism, adiposity, and blood pressure differentiate the first clinically available SGLT2 inhibitor dapagliflozin from other oral antidiabetic drugs. Yet, the mechanisms through which metabolic drugs affect blood pressure and their interaction with antihypertensive drugs are poorly understood. Blood pressure-lowering effects of metabolic drugs could be exploited in the clinical management of obese hypertensive patients with and without type 2 diabetes mellitus, particularly in patients with difficult to control arterial hypertension.Keywords
This publication has 48 references indexed in Scilit:
- Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysisBMJ Open, 2013
- Changes in the Prevalence, Treatment and Control of Hypertension in Germany? A Clinical-Epidemiological Study of 50.000 Primary Care PatientsPLOS ONE, 2012
- GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neuronsCardiovascular Research, 2010
- Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trialEuropean Heart Journal, 2010
- Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humansAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2008
- Resistant Hypertension: Diagnosis, Evaluation, and TreatmentHypertension, 2008
- Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study resultsJournal Of Hypertension, 2008
- Molecular Analysis of the SGLT2 Gene in Patients with Renal GlucosuriaJournal of the American Society of Nephrology, 2003
- Effect of Sibutramine on Weight Loss and Blood Pressure: A Meta‐analysis of Controlled TrialsObesity Research, 2003
- Differential Control of Systolic and Diastolic Blood PressureHypertension, 2000